Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Fsd Pharma Inc Cl B
(NQ:
HUGE
)
0.4667
+0.0013 (+0.28%)
Streaming Delayed Price
Updated: 3:57 PM EDT, Apr 19, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
42,577
Open
0.4597
Bid (Size)
0.4725 (1)
Ask (Size)
0.5400 (5)
Prev. Close
0.4654
Today's Range
0.4533 - 0.4780
52wk Range
0.4184 - 1.680
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
BioMedNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA:0K9A) Announces Expansion of Investigative Pipeline
April 17, 2024
Via
Investor Brand Network
Psychedelics Headlines: Dementia Prevention, Psychological Flexibility, Ancient Romans' Trips And More
April 17, 2024
Via
Benzinga
Performance
YTD
-48.14%
-48.14%
1 Month
-35.28%
-35.28%
3 Month
-46.72%
-46.72%
6 Month
-57.95%
-57.95%
1 Year
-69.89%
-69.89%
More News
Read More
FSD Pharma Expands Investigative Pipeline to Include Potential Weight Loss and Liver Health Formulations and Products
April 17, 2024
Via
ACCESSWIRE
BioMedNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Releases Update on Celly Nu Investment
April 15, 2024
Via
Investor Brand Network
FSD Pharma Provides Update on its Investment in Celly Nutrition Corp., a Company Launching a Product that can assist in Expediting Alcohol Metabolism and Faster Recovery from Alcohol Consumption
April 15, 2024
Via
ACCESSWIRE
FSD Pharma Announces Filing of Year-End 2023 Results
April 01, 2024
Via
ACCESSWIRE
Psychedelics Headlines: A Form Of Life, Treating Chronic Pain, Microdosing And More
March 30, 2024
Via
Benzinga
InvestorNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Subsidiary Partners with iNGENu CRO to Initiate MS Clinical Study
March 27, 2024
Via
Investor Brand Network
FSD Pharma Signs the Agreement With iNGENu CRO To Conduct a Clinical Study To Assess the Safety and Pharmacokinetics of Multiple Ascending Doses of Lucid-21-302 (Lucid-MS) in Healthy Adults
March 27, 2024
Via
ACCESSWIRE
Psychedelics Headlines: Substitution Survey, Frank Herbert's Magic Mushrooms, Celestial Plans And News Review
March 16, 2024
Via
Benzinga
FSD Pharma: A Compelling Value Proposition As UNBUZZD™ Positions To Dominate The Alcohol-Detox Functional Beverage Market
March 14, 2024
Via
AB Newswire
FSD Pharma’s Stake In Functional Beverage, UNBUZZD™, Is A Transformational Asset…Here’s Why
March 12, 2024
Via
AB Newswire
PsychedelicNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Takes First Step Toward Obtaining Permission for unbuzzd(TM) Phase-1b Clinical Trial
March 11, 2024
Via
Investor Brand Network
FSD Pharma Submits a Phase-1b Clinical Trial Application for Ethics Committee for its Proprietary Beverage unbuzzd(TM)
March 11, 2024
Via
ACCESSWIRE
PsychedelicNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Presents Positive Results on First-in-Human Phase 1 Study of Lucid-MS
March 05, 2024
Via
Investor Brand Network
FSD Pharma Presents Positive Results on First-In-Human Phase-1 study of Lucid-21-302 (Lucid-MS) at Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) 2024 Forum
March 05, 2024
Via
ACCESSWIRE
Psyched: New Evidence Shows Psilocybin As Anxiety Therapy, Open-Source Learning For Therapists, Enveric's Licensing Deals And More
March 04, 2024
Via
Benzinga
PsychedelicNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Board of Directors Approves Debt Settlement
February 28, 2024
Via
Investor Brand Network
FSD Pharma Announces Debt Settlement
February 28, 2024
Via
ACCESSWIRE
Biotech Company Develops Inebriation Remedy Beverage 'UNBUZZD'
February 26, 2024
Via
Benzinga
PsychedelicNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), Subsidiary Enter Agreement for Clinical Trial of Proprietary Blend Beverage
February 26, 2024
Via
Investor Brand Network
FSD Pharma Signs Agreement With Ingenu CRO to Conduct a Clinical Trial To Determine the Safety and Efficacy Effects of its Proprietary Blend Beverage unbuzzd(TM)
February 26, 2024
Via
ACCESSWIRE
PsychedelicNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Enters Market Offering Agreement
February 20, 2024
Via
Investor Brand Network
PsychedelicNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Announces Court of Appeal Dismisses Motion Brought by Dr. Raza Bokhari
February 06, 2024
Via
Investor Brand Network
Court of Appeal Dismisses Motion for Leave to Appeal Brought by Dr. Raza Bokhari, FSD Pharma Awards Total Approximately $3 Million
February 06, 2024
Via
ACCESSWIRE
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.